Skip to content

Study · Randomized controlled trial · n = 112 · 2024

3 results

Effects of chronic intranasal oxytocin on visual attention to faces vs. natural scenes in older adults.

Shoenfelt A, Pehlivanoglu D, Lin T, Ziaei M, Feifel D, Ebner NC

Psychoneuroendocrinology4 Mar 2024Cited by 9 (Europe PMC)

PMID38461634 (opens in a new tab)PMCIDPMC11699979 (opens in a new tab)DOI10.1016/j.psyneuen.2024.107018 (opens in a new tab)PepBankPUB-38461634
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialMechanism

    In older adults, 4 weeks of intranasal oxytocin made the decline in fixation duration to faces less pronounced than placebo.

    In plain wordsIn older adults, oxytocin reduced the drop in how long people looked at faces over time, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    IncreaseFixation duration to faces, pre- to post-intervention
    Study

    n = 112

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Fixation duration to both the faces and the natural scenes declined from pre- to post-intervention, however this decline was less pronounced among older adults in the OT compared to the P group for faces but not scenes.
    1 context sentence
    Summary · context
    One hundred and twelve generally healthy older adults (aged 55-95 years) underwent a randomized, placebo-controlled, double-blind, between-subject clinical trial in which they self-administered either OT or placebo (P) intranasally twice a day for 4 weeks.
  2. 02HumanRandomized controlled trialMechanism

    In older adults, intranasal oxytocin did not change the decline in fixation duration to natural scenes compared with placebo.

    In plain wordsIn older adults, oxytocin did not change how the time spent looking at natural scenes declined, compared with placebo.

    Peptide
    Oxytocin
    Outcome
    No significant changeFixation duration to natural scenes, pre- to post-intervention
    Study

    n = 112

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Fixation duration to both the faces and the natural scenes declined from pre- to post-intervention, however this decline was less pronounced among older adults in the OT compared to the P group for faces but not scenes.
    1 context sentence
    Summary · context
    One hundred and twelve generally healthy older adults (aged 55-95 years) underwent a randomized, placebo-controlled, double-blind, between-subject clinical trial in which they self-administered either OT or placebo (P) intranasally twice a day for 4 weeks.
  3. 03HumanRandomized controlled trialMechanism

    In older adults, face cues (emotional expression, gaze direction, age, sex) did not moderate the effect of oxytocin on fixation duration.

    In plain wordsIn older adults, the type of face shown did not change how oxytocin affected looking time.

    Peptide
    Oxytocin
    Outcome
    No significant changeModeration of treatment effect by face cues
    Study

    n = 112

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · intranasal · 4 weeksAs given in this study (human).

    Source sentences

    Summary
    Further, face cues (emotional expression, gaze direction, age, sex) did not moderate the treatment effect.
    1 context sentence
    Summary · context
    One hundred and twelve generally healthy older adults (aged 55-95 years) underwent a randomized, placebo-controlled, double-blind, between-subject clinical trial in which they self-administered either OT or placebo (P) intranasally twice a day for 4 weeks.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:48 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.